title: Differential suppression of dialysis patients' lymphocyte IFN-gamma production by glucocorticoids and cyclosporine.
abstract: IFN-gamma is a potent pro-inflammatory cytokine involved in the immunologic rejection of transplanted organs. Having previously demonstrated differential suppressive effects of methylprednisolone (MP), prednisolone (P) and cyclosporine (CsA) on dialysis patients' lymphocyte proliferative responses to phytohaemagglutinin (PHA), we studied the effects of these drugs on dialysis patients' lymphocyte IFN-gamma production during mitogenic and allogeneic (MLR) stimulation. The mean +/- SEM 50% inhibitory concentration (ng/ml) on cell proliferation was significantly lower for MP than P in PHA-stimulated haemodialysis (HD) patients' (35 +/- 7 vs 152 +/- 25, P < 0.001) and peritoneal dialysis (PD) patients' (35 +/- 11 vs 134 +/- 33, P = 0.001) cultures and in HD patients' MLR cultures (15 +/- 3 vs 48 +/- 9, P < 0.001). The mean +/- SEM fractional responses (PHA or MLR + drug/PHA or MLR) in culture supernatant IFN-gamma concentrations were significantly lower with 10(-7) M concentrations of MP than P in HD (0.19 +/- 0.05 vs 0.31 +/- 0.06, P = 0.01) and PD (0.30 +/- 0.11 vs 0.46 +/- 0.11, P < 0.05) PHA cultures and in HD MLR cultures (0.15 +/- 0.04 vs 0.28 +/- 0.07, P = 0.01). CsA (400 ng/ml) alone not only caused less than 50% inhibition of IFN-gamma production in 15/27 HD PHA, 6/14 PD PHA and 4/13 HD MLR cultures, but actually stimulated it in 9 HD and 5 PD PHA cultures. The results suggest that: (1) MP has greater immunosuppressive potential than P for renal transplant recipients; (2) the stimulation of IFN-gamma by CsA in some patients could be harmful in patients with initial allograft dysfunction; and (3) pre-transplant in-vitro assessment of recipients' PBMC responsiveness to glucocorticoids and CsA may help individualize the post-transplant immunosuppressive regimen.
authors.affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
authors.forename: W A
authors.initials: WA
authors.lastname: Briggs
authors.forename: Z H
authors.initials: ZH
authors.lastname: Gao
authors.forename: J J
authors.initials: JJ
authors.lastname: Xing
authors.forename: P J
authors.initials: PJ
authors.lastname: Scheel
authors.forename: L F
authors.initials: LF
authors.lastname: Gimenez
authors.forename: M J
authors.initials: MJ
authors.lastname: Choi
authors.forename: J F
authors.initials: JF
authors.lastname: Burdick
mesh_terms: D016572:Cyclosporine / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008775:Methylprednisolone / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011239:Prednisolone / Q000494:pharmacology*; D006435:Renal Dialysis; D014184:Transplantation, Homologous
chemical_list: D010835:Phytohemagglutinins; D007371:Interferon-gamma; D016572:Cyclosporine; D011239:Prednisolone; D008775:Methylprednisolone